z-logo
open-access-imgOpen Access
Suppression of collagen‐induced arthritis through adenovirus‐mediated transfer of a modified tumor necrosis factor α receptor gene
Author(s) -
Le Christine H.,
Nicolson A. Graham,
Morales Alejandro,
Sewell K. Lea
Publication year - 1997
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780400916
Subject(s) - tumor necrosis factor alpha , synovitis , arthritis , medicine , genetic enhancement , fusion gene , gene expression , gene transfer , immunology , cancer research , gene , biology , biochemistry
Objective . To evaluate the efficacy of systemic and intraarticular adenoviral transfer of a modified tumor necrosis factor α receptor (TNFαR) gene and its expression in rat collagen‐induced arthritis (CIA). Methods . Rats with CIA received injections of replication‐deficient adenovirus containing either a TNFα inhibitor (TNFI) gene or a control β galactosidase (β‐gal) gene. The TNFI gene codes for a fusion protein consisting of the human 55‐kd TNFαR and a mouse IgG heavy chain. Successful gene transfer was determined by serum TNFαR measurements and by histologic examination of injected joints with in situ blue staining. Results . Serum TNFαR levels were detectable for 8 days following systemic TNFI gene transfer. CIA severity was significantly suppressed by TNFI gene transfer, both prior to and following arthritis onset ( P = 0.0001, by repeated‐measures 2‐factor analysis of variance). Direct synovial TNFI gene transfer was successful, but induced an inflammatory response without any net TNFI benefit. Conclusion . Systemic adenoviral‐mediated transfer of the TNFI gene suppressed CIA during its transitory expression. Intraarticular gene transfer was limited by an adenoviral synovitis that was not overcome by delivery of the TNFI gene. TNFI is an excellent protein candidate for further therapeutic study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here